Cytokinetics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Cytokinetics wird ein Gewinn- und Umsatzwachstum von 36.7% bzw. 67.6% pro Jahr prognostiziert, während der Gewinn pro Aktie um 39.5% pro Jahr wachsen soll.

Wichtige Informationen

36.7%

Wachstumsrate der Gewinne

39.5%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.3%
Wachstumsrate der Einnahmen	67.6%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	19 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Here's Why We Think Cytokinetics, Incorporated's (NASDAQ:CYTK) CEO Compensation Looks Fair for the time being

May 09

Cytokinetics, Incorporated: Buyout Speculation Persists

Apr 01

Cytokinetics: CEO Talks Down Buyout Prospects

Mar 16

Cytokinetics Steps Up As Prime Target After Aficamten's HCM Triumph (Rating Upgrade)

Jan 12

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:CYTK - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	327	-473	-522	-413	13
12/31/2025	55	-628	-636	-561	15
12/31/2024	14	-588	-428	-435	16
9/30/2024	3	-576	-407	-404	N/A
6/30/2024	3	-545	-401	-399	N/A
3/31/2024	4	-531	-423	-422	N/A
12/31/2023	8	-526	-416	-414	N/A
9/30/2023	8	-527	-443	-438	N/A
6/30/2023	10	-540	-437	-426	N/A
3/31/2023	98	-431	-406	-395	N/A
12/31/2022	95	-389	-311	-300	N/A
9/30/2022	148	-282	-272	-246	N/A
6/30/2022	151	-216	-236	-201	N/A
3/31/2022	65	-258	-183	-140	N/A
12/31/2021	70	-215	-191	-143	N/A
9/30/2021	22	-229	-83	-46	N/A
6/30/2021	58	-156	-17	8	N/A
3/31/2021	59	-135	-7	10	N/A
12/31/2020	56	-127	-2	9	N/A
9/30/2020	54	-114	-68	-62	N/A
6/30/2020	19	-140	-101	-97	N/A
3/31/2020	22	-132	-98	-94	N/A
12/31/2019	27	-122	-94	-91	N/A
9/30/2019	31	-118	-86	-84	N/A
6/30/2019	36	-110	-97	-96	N/A
3/31/2019	35	-105	-99	-98	N/A
12/31/2018	32	-106	-102	-101	N/A
9/30/2018	22	-120	-114	-113	N/A
6/30/2018	18	-131	N/A	-106	N/A
3/31/2018	14	-132	N/A	-111	N/A
12/31/2017	13	-128	N/A	-102	N/A
9/30/2017	47	-80	N/A	0	N/A
6/30/2017	99	-14	N/A	14	N/A
3/31/2017	102	3	N/A	34	N/A
12/31/2016	106	16	N/A	37	N/A
9/30/2016	83	0	N/A	-51	N/A
6/30/2016	32	-42	N/A	-49	N/A
3/31/2016	33	-41	N/A	-47	N/A
12/31/2015	29	-38	N/A	5	N/A
9/30/2015	41	-20	N/A	7	N/A
6/30/2015	42	-17	N/A	8	N/A
3/31/2015	43	-15	N/A	7	N/A
12/31/2014	47	-15	N/A	-45	N/A
9/30/2014	50	-17	N/A	-49	N/A
6/30/2014	45	-23	N/A	-29	N/A
3/31/2014	38	-30	N/A	-13	N/A
12/31/2013	31	-34	N/A	-8	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CYTK wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: CYTK wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: CYTK wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: CYTKDie Einnahmen des Unternehmens (67.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: CYTKDie Einnahmen des Unternehmens (67.6% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von CYTK in 3 Jahren voraussichtlich hoch sein wird

Cytokinetics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates increase by 47%, EPS downgraded

Consensus revenue estimates fall by 14%

Consensus revenue estimates decrease by 23%

Consensus revenue estimates fall by 54%

Consensus revenue estimates increase by 10%

Price target decreased by 7.5% to US$86.06

Recent updates

Consensus revenue estimates increase by 47%, EPS downgraded

Cytokinetics, Incorporated Presents Additional Data from GALACTIC-HF At the American Heart Association Scientific Sessions 2024

Cytokinetics, Incorporated Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy At the American Heart Association Scientific Sessions 2024

Cytokinetics, Incorporated Presents Additional Data from GALACTIC-HF At the American Heart Association Scientific Sessions 2024

Cytokinetics: On The Cusp Of Commercialization

Consensus revenue estimates fall by 14%

Cytokinetics, Incorporated Announces Initiation of Phase 1 Clinical Study of CK-4015089

Now 20% overvalued after recent price rise

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Insider notifies of intention to sell stock

Cytokinetics, Incorporated to Report Q3, 2024 Results on Nov 06, 2024

Insider notifies of intention to sell stock

Cytokinetics Presents Additional Data from EQUOIA-HCM At the HCMS Scientific Sessions

Consensus revenue estimates decrease by 23%

Cytokinetics, Incorporated Presents Additional Data from SEQUOIA-HCM at the European Society of Cardiology Congress 2024

Insider notifies of intention to sell stock

Consensus revenue estimates fall by 54%

CEO, President & Director notifies of intention to sell stock

Cytokinetics: Aficamten Rolling NDA Submission Leads To Expansion Opportunities

Is Cytokinetics (NASDAQ:CYTK) Weighed On By Its Debt Load?

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

CEO, President & Director notifies of intention to sell stock

Cytokinetics, Incorporated to Report Q2, 2024 Results on Aug 08, 2024

Cytokinetics' Aficamten: Heartfelt Potential Amid Market Woes

CEO, President & Director recently sold US$622k worth of stock

Consensus revenue estimates increase by 10%

CEO, President & Director recently sold US$1.2m worth of stock

Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants

CEO, President & Director notifies of intention to sell stock

VP & Chief Accounting Officer recently sold US$636k worth of stock

New minor risk - Insider selling

Cytokinetics, Incorporated announced that it has received $49.999992 million in funding from Royalty Pharma Development Funding, LLC

Price target decreased by 7.5% to US$86.06

Consensus revenue estimates increase by 41%

Cytokinetics Decides To Go It Alone

Cytokinetics, Incorporated has completed a Follow-on Equity Offering in the amount of $500.000022 million.

Consensus revenue estimates decrease by 13%

Cytokinetics, Incorporated Announces Resignation of Sandford D. Smith as Board of Directors

Insider notifies of intention to sell stock

Here's Why We Think Cytokinetics, Incorporated's (NASDAQ:CYTK) CEO Compensation Looks Fair for the time being

Cytokinetics, Incorporated Announces CEDAR-HCM Is Open to Enrollment

Consensus revenue estimates decrease by 12%

Independent Chairman notifies of intention to sell stock

Cytokinetics, Incorporated Appoints Sung H. Lee as Executive Vice President, Effective as of May 8, 2024

Cytokinetics, Incorporated to Report Q1, 2024 Results on May 08, 2024

Insider exercised options and sold US$1.9m worth of stock

Cytokinetics, Incorporated, Annual General Meeting, May 15, 2024

Cytokinetics Presents Additional 48-Week Data from Forest-Hcm, the Open Label Extension Clinical Study of Aficamten, At the American College of Cardiology 73rd Annual Scientific Session

Cytokinetics, Incorporated: Buyout Speculation Persists

Cytokinetics: CEO Talks Down Buyout Prospects

Insider notifies of intention to sell stock

Consensus revenue estimates decrease by 49%, EPS upgraded

Cytokinetics, Incorporated Provides Revenue Guidance for 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Cytokinetics, Incorporated to Report Q4, 2023 Results on Feb 27, 2024

Cytokinetics, Incorporated Announces Resignation of Ching W. Jaw as Chief Financial Officer, Effective February 23, 2024

Cytokinetics, Incorporated Announces Resignation of Ching W. Jaw as Chief Financial Officer, Effective February 23, 2024

Cytokinetics, Incorporated Announces Resignation of Ching W. Jaw, Senior Vice President, Effective February 23, 2024

CEO, President & Director notifies of intention to sell stock

CEO, President & Director notifies of intention to sell stock

Novartis Pursuit of Cytokinetics Reportedly Cools

Novartis Pursuit of Cytokinetics Reportedly Cools

Cytokinetics Steps Up As Prime Target After Aficamten's HCM Triumph (Rating Upgrade)

Novartis Reportedly in Advanced Talks to Buy Cytokinetics

Novartis Reportedly in Advanced Talks to Buy Cytokinetics

CEO, President & Director notifies of intention to sell stock

Cytokinetics, Incorporated Announces Positive Results from Sequoia-Hcm, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy

New major risk - Revenue and earnings growth

Price target increased by 20% to US$74.39